Trials / Completed
CompletedNCT02611713
Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease
DUOdopa/Duopa in Patients With Advanced Parkinson's Disease (PD) - a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 213 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study is a non-interventional post-marketing observational study (PMOS) of participants with advanced Parkinson's disease (PD) treated with Duodopa/Duopa in a routine clinical setting. Effectiveness of treatment will be collected with physician and participant/caregiver health outcomes beginning with PMOS enrollment (baseline visit), at the start of Duodopa/Duopa treatment via percutaneous endoscopic gastrostomy-with jejunal extension (PEG-J), at regularly scheduled visits closest to Months 3 and 6, and every 6 months thereafter up to 36 months. An additional cohort of participants will be enrolled who in addition will be evaluated with a wearable device.
Conditions
Timeline
- Start date
- 2016-01-04
- Primary completion
- 2020-12-24
- Completion
- 2020-12-24
- First posted
- 2015-11-23
- Last updated
- 2021-12-15
Locations
54 sites across 10 countries: United States, Australia, Belgium, Hungary, Israel, Italy, Romania, Slovenia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02611713. Inclusion in this directory is not an endorsement.